Venus Remedies Fair Value
Venus Remedies fair value. Venus Remedies (VENUSREM) average fair value is ₹1681.9 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹1501.6 (+12.01%), fair value range ₹335.83–₹6703.43. For live price and a broader fundamental view, visit VENUSREM share price screener.
Fair Value Analysis Export
VENUSREM Fair Value vs Current Price — Valuation Summary
VENUSREM average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF).
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
VENUSREM Fair Value Analysis — Data Sources & Coverage
Venus Remedies financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Analyse VENUSREM promoter holding to track promoter, FII and institutional holdings.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
VENUSREM vs Healthcare Sector Peers — P/E, P/B & Market Cap
Venus Remedies P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 40.6 | 8.3 | ₹44,381 |
| Modern Diagnostic & Rese… | MDRC | - | 1.42 | ₹83 |
| Pharmaids Pharmaceuticals | PHARMAID | -28.7 | 2.2 | ₹100 |
| Glen Industries | GLEN | 15.7 | 1.97 | ₹250 |
| Broach Lifecare Hospital | BROACH | 90.7 | 0.82 | ₹8 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.